London, October 29, 2024 – GlaxoSmithKline (GSK), a global pharmaceutical giant, announced today that it has entered into an agreement to acquire a novel systemic lupus erythematosus (SLE) drug from Chimagen Biosciences, a Chinese biopharmaceutical company. The deal, potentially worth up to $850 million, marksGSK’s latest foray into China’s burgeoning pharmaceutical landscape.
The target drug, CMG1A46, is a dual-targeting CD19/CD20 T-cell mediated antibody. GSK will payan upfront payment of $300 million, with the potential for additional milestone payments of up to $550 million based on development and commercialization achievements.
This acquisition will bolster GSK’s existing autoimmune disease portfolio, whichalready includes the blockbuster SLE drug Benlysta (belimumab). The company plans to further develop and commercialize CMG1A46, focusing on B-cell driven autoimmune diseases such as SLE and lupus nephritis (LN), with potential expansion into related autoimmune conditions.
There remains a significant unmet need forpatients with lupus, particularly those who do not respond to current standard treatments, GSK stated in the announcement.
CMG1A46 is currently undergoing Phase I clinical trials in China for leukemia and lymphoma. GSK plans to initiate Phase I clinical trials for SLE in the first quarter of 2025.
Pharma Giants Turn Their Eyes to China
This acquisition is a testament to the growing strength of China’s pharmaceutical research and development capabilities. Increasingly, major multinational pharmaceutical companies are seeking partnerships and investments in China.
Last December, Shanghai Hansoh Pharmaceutical Group announced a licensing agreement with GSK for the overseas rights toHS-20093, an antibody-drug conjugate (ADC) drug. The deal could be worth up to $1.7 billion. In late October of the same year, Hansoh and GSK reached another exclusive licensing agreement for HS-20089, another ADC drug, potentially worth over $1.5 billion.
According to media reports, the total value of outbound transactions for ADC drugs developed by Chinese pharmaceutical companies has surpassed $35 billion, reflecting the emerging potential of this therapeutic area.
The US stock market has also witnessed a surge in interest surrounding Chinese drug companies going global. Summit Pharmaceuticals(SMMT), for instance, saw its share price soar from $3 to over $30 this year, currently trading at $21.
[Insert details about Summit Pharmaceuticals’ recent developments and the broader trend of Chinese drug companies going global, as provided in the original text.]
This latest acquisitionby GSK further underscores the growing importance of China in the global pharmaceutical landscape. As Chinese pharmaceutical companies continue to innovate and develop cutting-edge therapies, collaborations and investments with multinational giants are likely to become increasingly common.
References:
- GSK Press Release, October 29, 2024
*Caixin Global, GSK Acquires Chinese Lupus Drug for $850 Million - Financial Associated Press, Summit Pharmaceuticals Soars on Chinese Drug Deal
Note: This article is based on the provided information and has been written in a journalistic style. It includes key details about the acquisition,highlights the growing trend of pharma giants investing in China, and provides relevant context.
Views: 0